Clinical trial for children with high-risk neuroblastoma open
We are delighted to share that the SIOPEN High-Risk Neuroblastoma 2 trial is now officially open and ready to recruit at its first UK hospital, with more to follow soon.
In May 2020, we announced the award of £609, 762 in partnership with Solving Kids Cancer to open the UK sites of the SIOPEN High-Risk Neuroblastoma 2 trial. This latest European-wide study will look to answer important questions about the standard care protocols for children with high-risk neuroblastoma, and how they might be improved.
The opening of this trial is a great achievement by all involved, including the Cancer Research Clinical Trials Unit at the University of Birmingham.
Thanks to your support, children newly diagnosed with high-risk neuroblastoma in the UK can benefit from the same treatment opportunities as children across Europe.
What is the SIOPEN High-Risk Neuroblastoma 2 trial?
The SIOPEN High-Risk Neuroblastoma 2 (HR-NBL2) clinical trial is a 5-year study, recruiting 200 patients across 20 UK sites.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe.
By taking part in this pan-European study, it will enable a series of important randomised questions to be answered within the overall framework of the trial.
HR-NBL2 provides a clinical trial that ensures equal access to the very best treatments and care across the UK
It also provides a pathway for future innovative therapies to be safely administered and studied
The trial builds on the successes of the previous High-Risk Neuroblastoma Trial 1 (HR-NBL1) pan-European study developed by SIOPEN
Read more about the SIOPEN High-Risk Neuroblastoma 2 study, and the importance of funding sites in the UK.
Thank you
Thanks to our generous supporters, we provided funding of £175,000 to support this vital research. This trial offers real potential to develop more effective and kinder treatment for children with high-risk neuroblastoma in the UK - and it couldn’t have happened with your help.
To support more vital research into neuroblastoma, please donate today.